🇺🇸 FDA
Pipeline program

JZP258 (XYWAV)

JZP258-407

Approved small_molecule completed

Quick answer

JZP258 (XYWAV) for Idiopathic Hypersomnia is a Approved program (small_molecule) at Jazz Pharmaceuticals plc with 1 ClinicalTrials.gov record(s).

Program details

Company
Jazz Pharmaceuticals plc
Indication
Idiopathic Hypersomnia
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials